Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Robert Fitz

Internal Medicine Union, KY Medical Doctor

NPI 1447210711 CMS profile 110887

1808 Bristow Dr, Union, KY 41091

Open in the dashboard

General payments

$10,460

675 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Robert Fitz of Union, KY is reported in the CMS Open Payments database as having received $10,460 across 675 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $842 46
2024 General $1,060 61
2023 General $1,247 81
2022 General $1,325 97
2021 General $2,081 135
2020 General $1,757 101
2019 General $2,149 154

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Robert Fitz
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Robert Fitz were reported at $842. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Robert Fitz Internal Medicine median Middle half National median
2019 $2,149 $159 $48–$570 $163
2020 $1,757 $119 $33–$402 $114
2021 $2,081 $135 $37–$521 $132
2022 $1,325 $141 $42–$496 $149
2023 $1,247 $149 $45–$519 $160
2024 $1,060 $154 $47–$537 $164
2025 $842 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $1,510 98 payments
  2. Novo Nordisk Inc $1,218 82 payments
  3. GlaxoSmithKline, LLC. $1,027 81 payments
  4. AstraZeneca Pharmaceuticals LP $829 35 payments
  5. Amgen Inc. $622 35 payments
  6. Pfizer Inc. $578 44 payments
  7. Janssen Pharmaceuticals, Inc $413 19 payments
  8. Astellas Pharma US Inc $388 20 payments
  9. Lilly USA, LLC $306 21 payments
  10. Sanofi-Aventis U.S. LLC $263 16 payments
  11. Other $3,306 224 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $10,439 673 payments
  2. Education $21 2 payments
Products named General payments · program years 2019–2025
  1. TRELEGY ELLIPTA $768 62 payments
  2. Ozempic $688 48 payments
  3. FARXIGA $680 23 payments
  4. VRAYLAR Neuroscience $654 39 payments
  5. RYBELSUS $586 40 payments
  6. UBRELVY $447 34 payments
  7. XARELTO $413 19 payments
  8. Repatha $359 23 payments
  9. AIMOVIG $314 16 payments
  10. VRAYLAR Neuroscience $306 22 payments
  11. Other $7,920 551 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 154 drugs

Part D claims

10,595

Median for Internal Medicine: 777

Drug cost

$892,861

Median for Internal Medicine: $73,373

Branded share of claims

19.7%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 150 $246,296
Ozempic Semaglutide Brand 61 $108,887
Eliquis Apixaban Brand 95 $106,758
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 68 $82,949
Jardiance Empagliflozin Brand 32 $44,402
Xarelto Rivaroxaban Brand 32 $35,129
Rybelsus Semaglutide Brand 17 $34,964
Vraylar Cariprazine Hcl Brand 23 $32,736
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 27 $23,649
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 13 $18,180

The 10 drugs with the highest cost, of 154 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 50 billing codes

Paid by Medicare

$86,579

Of which drugs: $25,979

Medicare patients

342

Average age 73

Services billed

4,544

167 women, 175 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 42%
Chronic kidney disease 30%
Diabetes 28%
Ischemic heart disease 26%
Osteoporosis 20%
Depression 18%
COPD 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 75 97 $13,084
Vaccine for influenza for injection into muscle 90662 Office 106 107 $8,470
Pcv20 vaccine im 90677 Office 12 12 $3,496
Injection, methylprednisolone acetate, 1 mg J1010 Office 15 1,200 $109

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 28 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$199 23 —
RYBELSUS
$72 17 —
Ozempic
$72 61 —
UBRELVY
$64 — —
Veozah
$59 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 28 with Patron

Records

675 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record